Biomed Central Ltd

SHERPA: Unknown

People

  1. Dunn
    Dunn
  2. Morris
    Morris

Groups

  1. Department of Medicine (8)
  2. Head and Neck Service (8)
  3. Hematology-Oncology Fellows (8)
  4. Solid Tumor Oncology Division (8)
  5. Weinberg Fellows (8)
  6. Head and Neck Surgery (1)
  7. Surgery (1)
Search Within
  1. "Lara Dunn"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (1)
Groups
  1. Department of Medicine (8)
  2. Head and Neck Service (8)
  3. Hematology-Oncology Fellows (8)
  4. Solid Tumor Oncology Division (8)
  5. Weinberg Fellows (8)
  6. Head and Neck Surgery (1)

More Groups

People
  1. Lara Dunn (8)
  2. Luc Morris (1)
Years
  1. 2022 (2)
  2. 2021 (2)
  3. 2020 (3)
  4. 2019 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (8)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Chung, C.; Colevas, D.; Adkins, D.; Park, J. C.; Rodriguez, C.; Gibson, M.; Sukari, A.; Burtness, B.; Johnson, F.; Julian, R.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
    Meeting Abstract

    Afeyan, A.; Oliveira, G.; Egloff, A. M.; Zeng, Z.; Chernock, R.; Zhou, L.; Messier, C.; Lizotte, P.; Wolff, J.; Pfaff, K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the phase 1b dose-escalation study
    Meeting Abstract

    Altan, M.; Patnaik, A.; Barve, M.; Dunn, L.; Cobb, P.; Rosenberg, A.; Sharma, S.; Sukari, A.; Patel, M.; Wang, X.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase 1 trial of cue-101, a novel Hpv16 E7-Phla-Il2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic Hpv16+ head and neck cancer
    Meeting Abstract

    Chung, C.; Colevas, A. D.; Gibson, M.; Adkins, D.; Sukari, A.; Wirth, L.; Burtness, B.; Bauman, J.; Rodriguez, C.; Worden, F.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS)
    Meeting Abstract

    Lewis, K.; Peris, K.; Sekulic, A.; Stratigos, A.; Dunn, L.; Eroglu, Z.; Chang, A. L.; Migden, M.; Li, S.; Mohan, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Pai, S.; Adkins, D.; Wirth, L.; Chung, C.; Gibson, M.; Sukari, A.; Worden, F.; Colevas, D.; Saba, N.; Burtness, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing
    Journal Article

    Rischin, D.; Migden, M. R.; Lim, A. M.; Schmults, C. D.; Khushalani, N. I.; Hughes, B. G. M.; Schadendorf, D.; Dunn, L. A.; Hernandez-Aya, L.; Chang, A. L. S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase 2 efficacy and safety trial of ADU-S100 and pembrolizumab in adults with head and neck cancer
    Meeting Abstract

    Cohen, E.; Ferris, R.; Adkins, D.; Zandberg, D.; Dudek, A.; Mathew, M.; Dunn, L.; Grilley-Olson, J.; Sukari, A.; Redman, R.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save